BATS:BMY   Bristol-Myers Squibb Company
BMY seems oversold compared to EPS.
Expect a retest at 0.5 fib level.
Target $65
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.